申请人:Johnson Norbert Christopher
公开号:US20080058391A1
公开(公告)日:2008-03-06
Compounds of formula (I) and pharmaceutically acceptable salts thereof:
wherein; each of R
1
to R
4
is independently selected from hydrogen and C
1-4
alkyl and each of rings A and B independently is optionally further substituted by up to three substituents, each of which is independently selected from the group consisting of halogen, hydroxy, C
1-4
alkoxy, C
1-4
alkyl, C
1-5
alkanoyl, CF
3
, CF
3
O and cyano; with the proviso that ring A must contain at least one CF
3
group, are useful in the treatment of diseases and conditions mediated by modulation of use-dependent voltage-gated sodium channels.
化合物式(I)及其药学上可接受的盐:其中,R1至R4中的每个独立地选择自氢和C1-4烷基,环A和环B中的每个独立地选择自最多三个取代基,每个取代基独立地选择自卤素、羟基、C1-4烷氧基、C1-4烷基、C1-5烷酰基、CF3、CF3O和氰基;但是环A必须至少含有一个CF3基团。这些化合物在通过调节使用依赖性电压门控钠通道介导的疾病和病况的治疗中是有用的。